- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01654042
Prolongation of the Interval Between Prothrombin Time Tests in Stable Patients II (PRINT-II)
March 18, 2014 updated by: Sam Schulman, McMaster University
Prolongation of the Interval Between Prothrombin Time Tests in Stable Patients II (the PRINT II Study): a Randomized Controlled, Non-inferiority Trial Comparing 4-weekly With 12-weekly Testing and Dose-assessment
More than 2 million patients in North America are treated with warfarin - a "blood thinner" - to prevent blood clots in arteries or veins.
The treatment has to be monitored with a blood test and the dose changed accordingly every 1-4 weeks.
One third of the patients have very stable results and hardly ever have to change the dose.
The investigators wish to show that the level of control of the treatment with warfarin in these very stable patients is not worse with 12-weekly testing.
A pilot study the investigators performed indicated that 12-weekly testing would be safe but this has to be confirmed in a large study.
One third of patients taking warfarin have not had any changes in the dose for the past 6 months or longer.
These patients will be asked about participation in the study.
They will be randomized to testing and dosing every 4 or 12 weeks.
Each patient is in the study until it ends, which will be minimum 1 year and can be up to about 4 years.
The study is designed to show that 12-weekly testing does not significantly increase the risk for major bleeding or blood clots.
The results would be important for a large number of patients.
An increase of the interval between blood tests from 4 to 12 weeks would reduce the burden for these patients on life-long treatment considerably.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
The study is a randomized, controlled, open-label, multi-center non-inferiority trial to demonstrate that the interval between internation normalized ration (INR) tests can be extended from the recommended 4 weeks to 12 weeks for patients with stable INRs.
PROBE design.
Patients receiving warfarin therapy that have exhibited INR stability, defined as no change in maintenance dose for at least 6 months, are potentially eligible for enrolment in the study.
The primary outcome is a composite of major bleeding (ISTH criteria) plus objectively verified arterial or venous thromboembolism (excluding superficial thrombophlebitis) plus death related to thromboembolism.
Justification: the study is not reflecting a "trade-off" scenario where one regimen is expected to be more effective at the cost of increased harm compared to the other regimen.
Conversely, the potential disadvantage of the experimental regimen in this trial is increased variability in INR, which may result in an increased rate of low as well as high INRs and therefore potentially an increase of both types of clinical events.
Study Type
Interventional
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 2X2
- Hamilton Health Sciences - General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- long-term warfarin for prophylaxis of arterial embolism due to atrial fibrillation or mechanical heart valve replacement OR secondary prophylaxis after VTE
- therapeutic INR range of 2.0-3.0 or 2.5-3.5
- anticoagulation therapy has been managed by the study site for at least 6 months prior to enrollment
- warfarin maintenance dose has remained unchanged for the previous 6 months or longer
Exclusion Criteria:
- Age < 18 years
- Life expectancy of less than 1 year
- Congestive heart failure or other diagnosis where the condition or its treatment is expected to affect the stability of INR (e.g. cancer requiring chemotherapy)
- Attending physician believes that patient is not suitable for the study (for instance, psychiatric disorder; history of non-compliance; newly diagnosed disease which by itself, via the treatment required or the effects thereof may cause instability of INRs)
- Patients who perform self-testing
- Geographic inaccessibility
- Failure to obtain written consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Standard interval between PT testing
Prothrombin time (PT) is tested every 4 weeks, according to American College of Chest Physicians (ACCP) Guidelines up to 2008 for stable patients on warfarin.
|
|
Experimental: Prolonged interval between PT testing
Prothrombin time (PT) is tested every 12 weeks, according to suggestion in American College of Chest Physicians (ACCP) Guidelines of 2012 for stable patients on warfarin.
|
Patients in the intervention group will be scheduled for prothrombin time testing and dosing of warfarin every 12 weeks instead of every 4 weeks.
This has been suggested in the latest edition of the ACCP guidelines as a possibility for very stable patients.
In order to change this from a suggestion to a formal recommendation a study powered for clinically important outcomes is needed.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite of major bleeding and objectively verified arterial or venous thromboembolism
Time Frame: Average 3 years
|
The justification for a composite outcome including both bleeding and thromboembolism is that the study is not reflecting a "trade-off" scenario where one regimen is expected to be more effective at the cost of increased harm compared to the other regimen.
Conversely, the potential disadvantage of the experimental regimen in this trial is increased variability in prothrombin time, which may result in an increased rate of short as well as long prothrombin times and therefore potentially an increase of both types of clinical events.
|
Average 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause mortality
Time Frame: Average 3 years
|
Average 3 years
|
|
Any bleeding
Time Frame: Average 3 years
|
This is the composite of major and minor bleeding
|
Average 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Schulman S, Parpia S, Stewart C, Rudd-Scott L, Julian JA, Levine M. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med. 2011 Nov 15;155(10):653-9, W201-3. doi: 10.7326/0003-4819-155-10-201111150-00003.
- Pengo V, Barbero F, Biasiolo A, Pegoraro C, Cucchini U, Iliceto S. A comparison between six- and four-week intervals in surveillance of oral anticoagulant treatment. Am J Clin Pathol. 2003 Dec;120(6):944-7. doi: 10.1309/U716-4E0X-H5UE-RKRV.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2014
Primary Completion (Anticipated)
April 1, 2018
Study Completion (Anticipated)
October 1, 2018
Study Registration Dates
First Submitted
July 21, 2012
First Submitted That Met QC Criteria
July 26, 2012
First Posted (Estimate)
July 31, 2012
Study Record Updates
Last Update Posted (Estimate)
March 20, 2014
Last Update Submitted That Met QC Criteria
March 18, 2014
Last Verified
March 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Respiratory Tract Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Lung Diseases
- Embolism and Thrombosis
- Atherosclerosis
- Arrhythmias, Cardiac
- Heart Diseases
- Embolism
- Peripheral Arterial Disease
- Peripheral Vascular Diseases
- Atrial Fibrillation
- Thrombosis
- Venous Thrombosis
- Heart Valve Diseases
- Pulmonary Embolism
Other Study ID Numbers
- PRINT-II-2012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
Marissa JarosinskiRecruitingPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Vascuros Medical Pte LtdNovella ClinicalUnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery DiseaseSingapore, Belgium, Germany
-
Western Vascular Institute, IrelandRecruitingPeripheral Arterial Occlusive DiseaseIreland
-
Jena University HospitalAngioDroid s.r.l., Bologna (Italy)CompletedPeripheral Arterial Occlusive DiseaseGermany
-
Seoul National University HospitalAstellas Pharma Korea, Inc.CompletedPeripheral Arterial Occlusive DiseaseKorea, Republic of
-
Heidelberg UniversityTerminatedPeripheral Arterial Occlusive DiseaseGermany
-
Johann Wolfgang Goethe University HospitalSuspendedPeripheral Arterial Occlusive DiseaseGermany
Clinical Trials on Prolonged interval between PT testing
-
University of Texas at AustinCompletedCardiovascular Diseases | Vascular Diseases | Glucose Metabolism Disorders | Arteriosclerosis | Arterial Occlusive Diseases | Atherosclerosis | Insulin Resistance | Hyperinsulinism | Metabolic Syndrome X | Metabolic DiseaseUnited States
-
Hospital Clinic of BarcelonaHospital Son Espases; Hospital del Mar; Hospital Universitario La Fe; Instituto... and other collaboratorsUnknownRectal Cancer | Neoadjuvant TherapySpain
-
AC Camargo Cancer CenterRecruiting
-
Sinovac Biotech Co., LtdCompleted
-
University of ExeterUniversity of British ColumbiaTerminatedEndothelial Dysfunction | Cardiovascular Risk FactorUnited Kingdom
-
University of California, San FranciscoAgency for Healthcare Research and Quality (AHRQ)Completed
-
Sheba Medical CenterRecruitingGlaucoma | Glaucoma; DrugsIsrael
-
University of Texas at AustinUnknownHypertriglyceridemia | Sedentary BehaviorUnited States
-
Changhai HospitalNot yet recruitingPancreatitis, ChronicChina
-
Dexa Medica GroupCompletedMetformin XR BE Study in Healthy Volunteers With Single and Multiple DoseIndonesia